+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neutropenia Treatment Market by Treatment Type, Therapy Class, Route of Administration, Distribution Channel, End User, Patient Age Group, Severity - Global Forecast to 2030- Product Image
Neutropenia Treatment Market by Treatment Type, Therapy Class, Route of Administration, Distribution Channel, End User, Patient Age Group, Severity - Global Forecast to 2030- Product Image
Sale

Neutropenia Treatment Market by Treatment Type, Therapy Class, Route of Administration, Distribution Channel, End User, Patient Age Group, Severity - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674204
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neutropenia Treatment Market grew from USD 15.08 billion in 2024 to USD 15.85 billion in 2025. It is expected to continue growing at a CAGR of 5.02%, reaching USD 20.24 billion by 2030.

Shaping the Future of Neutropenia Care

Neutropenia represents a critical challenge within oncology and infectious disease care, affecting patient outcomes and healthcare resource allocation on a global scale. As therapies evolve and the burden of neutrophil deficiency gains prominence, understanding the full spectrum of treatment modalities and market dynamics becomes indispensable. This executive summary offers decision-makers a concise yet comprehensive overview of the latest advancements, regulatory shifts, and competitive forces reshaping the neutropenia treatment domain.

Grounded in meticulous analysis of clinical developments, regulatory environments, and commercial strategies, this document emphasizes the strategic imperatives for stakeholders at every level. By illuminating prevailing trends and highlighting emerging opportunities, it establishes a solid foundation for informed investment, product development, and partnership decisions. The insights herein are distilled from a robust research framework designed to capture the multifaceted dimensions of market performance without resorting to speculative forecasts, ensuring actionable clarity and confidence.

Transformative Forces Driving Neutropenia Treatment Evolution

Neutropenia treatment has undergone a profound transformation driven by advances in biopharmaceutical innovation and evolving patient expectations. Beyond traditional growth factors, the introduction of novel biosimilars has accelerated access, reduced cost barriers, and intensified competitive pressures. Simultaneously, precision medicine approaches and targeted supportive care protocols are refining therapeutic regimens, shifting paradigms from broad-spectrum interventions to highly individualized strategies.

Regulatory bodies have responded with adaptive pathways that streamline approval without compromising safety or efficacy, thereby fostering a fertile environment for emerging players. Moreover, digital health platforms and telemedicine integration are extending continuity of care, ensuring timely monitoring of neutrophil counts and patient adherence. These confluence of technological, clinical, and regulatory shifts is redefining value propositions, compelling incumbents and new entrants alike to rethink portfolio strategies and commercial models.

Unpacking the 2025 US Tariff Impact on Neutropenia Therapies

The introduction of a new tariff regime in early 2025 has injected fresh complexity into the cost structure of neutropenia therapies within the United States. Manufacturers face elevated import levies on active pharmaceutical ingredients and finished biologics, prompting a reassessment of pricing strategies and supply chain configurations. Although incremental duty increases initially strained margins, proactive contract renegotiations and localized manufacturing expansions have mitigated long-term impacts.

In parallel, downstream stakeholders-distributors and payers-have adjusted reimbursement frameworks, catalyzing collaborative value-based agreements that emphasize outcomes and total cost of care rather than unit pricing alone. While some market participants have absorbed tariff-related expenses through operational efficiencies, others have transferred costs partially to healthcare providers and patients. Consequently, the 2025 tariff landscape has stimulated innovation in procurement, contracting, and market access, ultimately reinforcing the value proposition of biosimilar alternatives.

Insightful Breakdowns Across Neutropenia Treatment Segments

Market segmentation in neutropenia treatment reveals pronounced differentiation across therapeutic categories, delivery mechanisms, and end-user environments. Within the treatment type dimension, Filgrastim, Lenograstim, and Pegfilgrastim each occupy distinct positions, with Filgrastim subdivided into 300 mcg, 480 mcg, and 600 mcg doses, Lenograstim offered in 3 mg and 5 mg formats, and Pegfilgrastim standardized at 6 mg. This granularity enables targeted clinical adoption and pricing optimization at the granular dose level.

Examining therapy class, biosimilar and originator products contend on efficacy parity, safety profiles, and cost-effectiveness, driving varied uptake across geographic and payer segments. The route of administration further segments the market between intravenous injection and subcutaneous injection, influencing hospital workflows and patient convenience. Distribution channel distinctions encompass hospital pharmacy settings-both inpatient and outpatient-as well as online and retail pharmacies, which include chain and independent outlets. End user analysis differentiates among ambulatory care centers, clinics, home care environments, and hospital systems subdivided into private and public institutions. Finally, patient age categorization spans adult, geriatric, and pediatric cohorts while severity stratification addresses mild, moderate, and severe presentations. Collectively, these dimensions inform product positioning, stakeholder engagement, and tailored access strategies.

Geographic Trends Defining Neutropenia Market Growth

Geographic variations in neutropenia treatment markets underscore the importance of region-specific strategies. In the Americas, established reimbursement systems and a high prevalence of oncology protocols have fostered rapid adoption of novel biologics and biosimilars, supported by robust clinical trial networks. Meanwhile, the Europe, Middle East & Africa region exhibits a dichotomy between mature Western European markets with stringent regulatory harmonization and emerging economies where healthcare infrastructure expansion drives incremental demand for cost-effective therapies.

Asia-Pacific presents a dynamic landscape characterized by diverse regulatory frameworks and shifting demographic patterns. In developed markets such as Japan and Australia, premium pricing models prevail, whereas in rapidly growing economies like China and India, volume-driven access programs and local manufacturing partnerships are gaining traction. These regional disparities in regulatory timelines, payer structures, and patient care delivery necessitate adaptable commercial strategies and tailored stakeholder engagement to optimize market penetration and sustainable growth.

Competitive Landscape Highlighting Key Industry Players

The competitive landscape in neutropenia treatment is marked by established biopharmaceutical leaders and a new wave of biosimilar manufacturers. Market incumbents leverage extensive clinical data packages, longstanding relationships with healthcare providers, and integrated supply chains to maintain share. Concurrently, biosimilar entrants emphasize cost leadership, lean manufacturing processes, and strategic alliances to accelerate market entry and secure formulary placements.

Key players differentiate through value-added services, including patient support programs, digital adherence tools, and multi-channel educational initiatives aimed at both clinicians and payers. Advanced biologics developers invest heavily in real-world evidence generation to demonstrate long-term safety and health economics benefits, while smaller innovators target niche segments such as pediatric or severe neutropenia indications. This competitive interplay drives continuous improvement in product offerings, pricing dynamics, and service models across the global market.

Strategic Actions to Propel Market Leadership

To capitalize on evolving market dynamics and regulatory shifts, industry leaders should refine their strategic imperatives. First, investing in localized manufacturing capacities will mitigate tariff exposure and strengthen supply resilience. Second, forging collaborative value-based agreements with payers that reward patient outcomes rather than volume will solidify market access and foster sustainable reimbursement environments. Third, expanding digital health integrations-such as remote monitoring platforms and telehealth-enabled dosing support-will enhance patient adherence and elevate the standard of care.

Moreover, tailoring segmentation strategies through precise dose-level and route-of-administration targeting will unlock incremental revenue streams and improve stakeholder engagement. Partnerships with specialized contract research organizations and real-world evidence consortia will expedite data generation, reinforcing differentiation in both originator and biosimilar portfolios. Finally, cultivating cross-functional alliances that bridge commercial, medical, and market access teams will ensure cohesive execution of product launches and lifecycle management initiatives.

Rigorous Methodological Framework Underpinning Analysis

This analysis is grounded in a multi-faceted research framework combining primary and secondary data sources. Primary research involved in-depth interviews with industry executives, key opinion leaders, payers, and healthcare providers to capture real-time perspectives on clinical adoption, reimbursement strategies, and supply chain adaptations. Secondary sources comprised regulatory filings, peer-reviewed publications, corporate presentations, government databases, and reputable trade journal articles.

Data synthesis employed qualitative thematic analysis and rigorous triangulation to ensure consistency across disparate inputs. Market drivers, challenges, and competitive benchmarks were systematically validated through cross-referencing of stakeholder insights and publicly available intelligence. The methodology emphasizes transparency and reproducibility, eschewing speculative forecasts while delivering a robust portrayal of current market dynamics and strategic inflection points.

Consolidated Outcomes Steering Strategic Decisions

The collective findings of this executive summary underscore the intricate interplay between regulatory evolution, competitive forces, and regional disparities in shaping the neutropenia treatment market. By illuminating tariff impacts, segmentation nuances, and geographic trends, stakeholders gain a comprehensive vantage point from which to navigate an increasingly complex therapeutic landscape.

Strategic imperatives-ranging from manufacturing localization and value-based contracting to digital health integration and targeted portfolio optimization-emerge as critical levers for capturing sustainable growth. The evidence-based insights herein provide a clear foundation for informed decision-making, enabling industry participants to align resources, refine priorities, and orchestrate coordinated market entry and expansion efforts with confidence.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Filgrastim
      • 300 mcg
      • 480 mcg
      • 600 mcg
    • Lenograstim
      • 3 mg
      • 5 mg
    • Pegfilgrastim
      • 6 mg
  • Therapy Class
    • Biosimilar
    • Originator
  • Route Of Administration
    • Intravenous Injection
    • Subcutaneous Injection
  • Distribution Channel
    • Hospital Pharmacy
      • Inpatient Pharmacy
      • Outpatient Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • End User
    • Ambulatory Care Centers
    • Clinics
    • Home Care
    • Hospitals
      • Private
      • Public
  • Patient Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Severity
    • Mild
    • Moderate
    • Severe
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Amgen Inc.
  • Sandoz International GmbH
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Coherus BioSciences, Inc.
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Biocon Limited
  • Celltrion, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neutropenia Treatment Market, by Treatment Type
8.1. Introduction
8.2. Filgrastim
8.2.1. 300 mcg
8.2.2. 480 mcg
8.2.3. 600 mcg
8.3. Lenograstim
8.3.1. 3 mg
8.3.2. 5 mg
8.4. Pegfilgrastim
8.4.1. 6 mg
9. Neutropenia Treatment Market, by Therapy Class
9.1. Introduction
9.2. Biosimilar
9.3. Originator
10. Neutropenia Treatment Market, by Route of Administration
10.1. Introduction
10.2. Intravenous Injection
10.3. Subcutaneous Injection
11. Neutropenia Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.2.1. Inpatient Pharmacy
11.2.2. Outpatient Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Neutropenia Treatment Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Clinics
12.4. Home Care
12.5. Hospitals
12.5.1. Private
12.5.2. Public
13. Neutropenia Treatment Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
14. Neutropenia Treatment Market, by Severity
14.1. Introduction
14.2. Mild
14.3. Moderate
14.4. Severe
15. Americas Neutropenia Treatment Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Neutropenia Treatment Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Neutropenia Treatment Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Amgen Inc.
18.3.2. Sandoz International GmbH
18.3.3. Pfizer Inc.
18.3.4. Teva Pharmaceutical Industries Ltd.
18.3.5. Viatris Inc.
18.3.6. Coherus BioSciences, Inc.
18.3.7. Fresenius Kabi AG
18.3.8. Intas Pharmaceuticals Ltd.
18.3.9. Biocon Limited
18.3.10. Celltrion, Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. NEUTROPENIA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. NEUTROPENIA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. NEUTROPENIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2030 (%)
FIGURE 20. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. NEUTROPENIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. NEUTROPENIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NEUTROPENIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 6 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES NEUTROPENIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 79. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 80. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 81. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 82. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 83. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 84. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 87. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 88. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 90. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. CANADA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 92. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 94. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 95. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 96. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 100. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. MEXICO NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 158. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 160. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 161. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 162. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 163. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 166. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 167. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 169. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 170. GERMANY NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 171. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 172. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 173. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 174. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 175. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 179. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 180. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 182. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 183. FRANCE NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 197. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 199. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 200. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 201. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 202. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 205. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 206. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 208. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. ITALY NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 210. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 212. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 213. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 214. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 215. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 218. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 219. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 221. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 222. SPAIN NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 262. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 263. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 264. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 265. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 266. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 267. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 270. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 271. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 273. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 274. DENMARK NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 275. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 277. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 280. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 288. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 289. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 290. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 291. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 292. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 293. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 296. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 297. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 299. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 300. QATAR NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 301. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 302. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 303. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 304. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 305. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 306. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 309. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 310. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 312. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 313. FINLAND NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 314. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 315. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 316. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 317. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 318. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 319. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 320. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 322. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 323. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 325. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 326. SWEDEN NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
TABLE 327. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 328. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2030 (USD MILLION)
TABLE 329. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2030 (USD MILLION)
TABLE 330. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2030 (USD MILLION)
TABLE 331. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 332. NIGERIA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2

Companies Mentioned

The companies profiled in this Neutropenia Treatment market report include:
  • Amgen Inc.
  • Sandoz International GmbH
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Coherus BioSciences, Inc.
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Biocon Limited
  • Celltrion, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 15.85 Billion
Forecasted Market Value ( USD ) by 2030 $ 20.24 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 195 Pages
  • Global
From
Neutropenia Treatment Market Report by Treatment, Distribution channel, and Region 2025-2033 - Product Image

Neutropenia Treatment Market Report by Treatment, Distribution channel, and Region 2025-2033

  • Report
  • 143 Pages
  • Global
From
Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report - Product Image

Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report

  • Report
  • 381 Pages
  • Global
From
Febrile Neutropenia Market - Product Image

Febrile Neutropenia Market

  • Report
  • 250 Pages
  • Global
From
Febrile Neutropenia Global Market Report 2025 - Product Image

Febrile Neutropenia Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Neutropenia Drug Market

Neutropenia Drug is a type of drug used to treat immune disorders, specifically those that involve a decrease in the number of neutrophils, a type of white blood cell. Neutropenia can be caused by a variety of conditions, including chemotherapy, radiation therapy, and certain infections. Neutropenia drugs are designed to increase the number of neutrophils in the body, helping to reduce the risk of infection and other complications. These drugs are typically administered intravenously or orally, depending on the severity of the condition. The Neutropenia Drug market is highly competitive, with a number of companies offering products to treat this condition. Some of the major players in this market include Amgen, Novartis, Pfizer, Merck, and Roche. These companies offer a range of products, including monoclonal antibodies, cytokines, and other biologics. Additionally, there are a number of smaller companies that offer generic versions of these drugs. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.